Stock Events

Stock Events

Kiora Pharmaceuticals 

€0.42
46
+€0+0% Friday 07:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
1.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.78
0.53
1.85
3.17
Expected EPS
-0.6136529999999999
Actual EPS
N/A

Financials

22.16%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
30.32MRevenue
6.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7EY.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the development of treatments for eye diseases, directly competing with Kiora's focus on ophthalmic diseases.
Novavax
NVAX
Mkt Cap1.36B
Novavax, while primarily known for vaccines, is expanding into therapeutic areas that could overlap with Kiora's research interests.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, through its eye health division, competes in the same ophthalmic market as Kiora Pharmaceuticals.
Biogen
BIIB
Mkt Cap22.63B
Biogen's expansion into therapies for neurological conditions includes research into diseases that can affect vision, overlapping with Kiora's interests.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology sector, competing with Kiora Pharmaceuticals.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse portfolio that includes treatments for conditions potentially overlapping with Kiora's focus areas.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceuticals and medical devices divisions, competes in various healthcare sectors, including eye health.
Novartis
NVS
Mkt Cap237.61B
Novartis has a significant ophthalmology division, directly competing with Kiora Pharmaceuticals in developing treatments for eye diseases.

About

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Show more...
CEO
ISIN
US49721T5074
WKN
000A40EG5

Listings

F
DE
7EY.F
BOATS
BOATS
KPRX.BOATS
OTC Link
US
KPHMW
XNAS
US
KPRX

0 Comments

Share your thoughts

FAQ

What is Kiora Pharmaceuticals stock price today?▼
The current price of 7EY.F is €0.42 EUR — it has increased by +0% in the past 24 hours. Watch Kiora Pharmaceuticals stock price performance more closely on the chart.
What is Kiora Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kiora Pharmaceuticals stocks are traded under the ticker 7EY.F.
What is Kiora Pharmaceuticals market cap?▼
Today Kiora Pharmaceuticals has the market capitalization of 1.55M
When is the next Kiora Pharmaceuticals earnings date?▼
Kiora Pharmaceuticals is going to release the next earnings report on May 08, 2026.
What were Kiora Pharmaceuticals earnings last quarter?▼
7EY.F earnings for the last quarter are 0.01 EUR per share, whereas the estimation was -0.64 EUR resulting in a +101.36% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Kiora Pharmaceuticals revenue for the last year?▼
Kiora Pharmaceuticals revenue for the last year amounts to 30.32M EUR.
What is Kiora Pharmaceuticals net income for the last year?▼
7EY.F net income for the last year is 6.72M EUR.
When did Kiora Pharmaceuticals complete a stock split?▼
The last stock split for Kiora Pharmaceuticals was on June 11, 2024 with a ratio of 1:9.